1
|
Ferrando AA: The role of NOTCH1 signaling
in T-ALL. Hematology Am Soc Hematol Educ Program. 353–361.
2009.PubMed/NCBI
|
2
|
Chiaretti S and Foà R: T-cell acute
lymphoblastic leukemia. Haematologica. 94:160–162. 2009. View Article : Google Scholar : PubMed/NCBI
|
3
|
Weng AP, Ferrando AA, Lee W, Morris JP IV,
Silverman LB, Sanchez-Irizarry C, Blacklow SC, Looks AT and Aster
JC: Activating mutations of NOTCH1 in human T cell acute
lymphoblastic leukemia. Science. 306:269–271. 2004. View Article : Google Scholar : PubMed/NCBI
|
4
|
Haydu JE, De Keersmaecker K, Duff MK,
Paietta E, Racevskis J, Wiernik PH, Rowe JM and Ferrando A: An
activating intragenic deletion in NOTCH1 in human T-ALL. Blood.
119:5211–5214. 2012. View Article : Google Scholar : PubMed/NCBI
|
5
|
Groth C and Fortini ME: Therapeutic
approaches to modulating Notch signaling: Current challenges and
future prospects. Semin Cell Dev Biol. 23:465–472. 2012. View Article : Google Scholar : PubMed/NCBI
|
6
|
Takebe N, Nguyen D and Yang SX: Targeting
notch signaling pathway in cancer: Clinical development advances
and challenges. Pharmacol Ther. 141:140–149. 2014. View Article : Google Scholar : PubMed/NCBI
|
7
|
Bray SJ: Notch signalling: A simple
pathway becomes complex. Nat Rev Mol Cell Biol. 7:678–689. 2006.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Siemers ER, Quinn JF, Kaye J, Farlow MR,
Porsteinsson A, Tariot P, Zoulnouni P, Galvin JE, Holtzman DM,
Knopman DS, et al: Effects of a gamma-secretase inhibitor in a
randomized study of patients with Alzheimer disease. Neurology.
66:602–604. 2006. View Article : Google Scholar : PubMed/NCBI
|
9
|
Deangelo DJ, Stone RM, Silverman LB, Stock
W, Attar EC, Fearen I, Dallob A, Matthews C, Stone J, Freedman SJ
and Aster J: A phase I clinical trial of the notch inhibitor
MK-0752 in patients with T-cell acute lymphoblastic
leukemia/lymphoma (T-ALL) and other leukemias. J Clin Oncol (ASCO
Annual Meeting Proceedings). 24:65852006.
|
10
|
Kolb EA, Gorlick R, Keir ST, Maris JM,
Lock R, Carol H, Kurmasheva RT, Reynolds CP, Kang MH, Wu J, et al:
Initial testing (stage 1) by the pediatric preclinical testing
program of RO4929097, a γ-secretase inhibitor targeting notch
signaling. Pediatr Blood Cancer. 58:815–818. 2012. View Article : Google Scholar : PubMed/NCBI
|
11
|
Messersmith WA, Shapiro GI, Cleary JM,
Jimeno A, Dasari A, Huang B, Shaik MN, Cesari R, Zheng X, Reynolds
JM, et al: A Phase I, dose-finding study in patients with advanced
solid malignancies of the oral γ-secretase inhibitor PF-03084014.
Clin Cancer Res. 21:60–67. 2015. View Article : Google Scholar : PubMed/NCBI
|
12
|
Litzow MR and Ferrando AA: How I treat
T-cell acute lymphoblastic leukemia in adults. Blood. 126:833–841.
2015. View Article : Google Scholar : PubMed/NCBI
|
13
|
Amarante-Mendes GP and Griffith TS:
Therapeutic applications of TRAIL receptor agonists in cancer and
beyond. Pharmacol Ther. 155:117–131. 2015. View Article : Google Scholar : PubMed/NCBI
|
14
|
Hellwig CT and Rehm M: TRAIL signaling and
synergy mechanisms used in TRAIL-based combination therapies. Mol
Cancer Ther. 11:3–13. 2012. View Article : Google Scholar : PubMed/NCBI
|
15
|
Akahane K, Inukai T, Zhang X, Hirose K,
Kuroda I, Goi K, Honna H, Kagami K, Nakazawa S, Endo K, et al:
Resistance of T-cell acute lymphoblastic leukemia to tumor necrosis
factor-related apoptosis-inducing ligand-mediated apoptosis. Exp
Hematol. 38:885–895. 2010. View Article : Google Scholar : PubMed/NCBI
|
16
|
Bijnsdorp IV, Giovannetti E and Peters GJ:
Analysis of drug interactions. Methods Mol Biol. 731:421–434. 2011.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
18
|
Van Vlierberghe P and Ferrando A: The
molecular basis of T cell acute lymphoplastic leukemia. J Clin
Invest. 122:3398–3406. 2012. View
Article : Google Scholar : PubMed/NCBI
|
19
|
Olsauskas-Kuprys R, Zlobin A and Osipo C:
Gamma secretase inhibitors of Notch signaling. Onco Targets Ther.
6:943–955. 2013.PubMed/NCBI
|
20
|
Diaz-Padilla I, Wilson MK, Clarke BA,
Hirte HW, Welch SA, Mackay HJ, Biagi JJ, Reedijk M, Weberpals JI,
Fleming GF, et al: A phase II study of single-agent RO4929097, a
gamma-secretase inhibitor of Notch signaling, in patients with
recurrent platinum-resistant epithelial ovarian cancer: A study of
the Princess Margaret, Chicago and California phase II consortia.
Gynecol Oncol. 137:216–222. 2015. View Article : Google Scholar : PubMed/NCBI
|
21
|
Lee SM, Moon J, Redman BG, Chidiac T,
Flaherty LE, Zha Y, Othus M, Ribas A, Sondak VK, Gajewski TF and
Margolin KA: Phase 2 study of RO4929097, a gamma-secretase
inhibitor, in metastatic melanoma: SWOG 0933. Cancer. 121:432–440.
2015. View Article : Google Scholar : PubMed/NCBI
|
22
|
LoConte NK, Razak AR, Ivy P, Tevaarwerk A,
Leverence R, Kolesar J, Siu L, Lubner SJ, Mulkerin DL, Schelman WR,
et al: A multicenter phase 1 study of γ -secretase inhibitor
RO4929097 in combination with capecitabine in refractory solid
tumors. Invest New Drugs. 33:169–176. 2015. View Article : Google Scholar : PubMed/NCBI
|
23
|
Richter S, Bedard PL, Chen EX, Clarke BA,
Tran B, Hotte SJ, Stathis A, Hirte HW, Razak AR, Reedijk M, et al:
A phase I study of the oral gamma secretase inhibitor R04929097 in
combination with gemcitabine in patients with advanced solid tumors
(PHL-078/CTEP 8575). Invest New Drugs. 32:243–249. 2014. View Article : Google Scholar : PubMed/NCBI
|
24
|
Sahebjam S, Bedard PL, Castonguay V, Chen
Z, Reedijk M, Liu G, Cohen B, Zhang WJ, Clarke B, Zhang T, et al: A
phase I study of the combination of RO4929097 and cediranib in
patients with advanced solid tumours. Br J Cancer. 109:943–949.
2013. View Article : Google Scholar : PubMed/NCBI
|
25
|
Diaz-Padilla I, Hirte H, Oza AM, Clarke
BA, Cohen B, Reedjik M, Zhang T, Kamel-Reid S, Ivy SP, Hotte SJ, et
al: A phase Ib combination study of RO4929097, a gamma-secretase
inhibitor, and temsirolimus in patients with advanced solid tumors.
Invest New Drugs. 31:1182–1191. 2013. View Article : Google Scholar : PubMed/NCBI
|
26
|
Portanova P, Notaro A, Pellerito O,
Sabella S, Giuliano M and Calvaruso G: Notch inhibition restores
TRAIL-mediated apoptosis via AP1-dependent upregulation of DR4 and
DR5 TRAIL receptors in MDA-MB-231 breast cancer cells. Int J Oncol.
43:121–130. 2013.PubMed/NCBI
|
27
|
Wang S and El-Deiry WS: TRAIL and
apoptosis induction by TNF-family death receptors. Oncogene.
22:8628–8633. 2003. View Article : Google Scholar : PubMed/NCBI
|
28
|
Wang C, Qi R, Li N, Wang Z, An H, Zhang Q,
Yu Y and Cao X: Notch1 signaling sensitizes tumor necrosis
factor-related apoptosis-inducing ligand-induced apoptosis in human
hepatocellular carcinoma cells by inhibiting Akt/Hdm2-mediated p53
degradation and up-regulating p53-dependent DR5 expression. J Biol
Chem. 284:16183–16190. 2009. View Article : Google Scholar : PubMed/NCBI
|
29
|
Naik S, MacFarlane M and Sarin A: Notch4
signaling confers susceptibility to TRAIL-induced apoptosis in
breast cancer cells. J Cell Biochem. 116:1371–1380. 2015.
View Article : Google Scholar : PubMed/NCBI
|
30
|
Li H, Zhu H, Xu CJ and Yuan J: Cleavage of
BID by caspase 8 mediates the mitochondrial damage in the Fas
pathway of apoptosis. Cell. 94:491–501. 1998. View Article : Google Scholar : PubMed/NCBI
|
31
|
Schug ZT, Gonzalvez F, Houtkooper RH, Vaz
FM and Gottlieb E: BID is cleaved by caspase-8 within a native
complex on the mitochondrial membrane. Cell Death Differ.
18:538–548. 2011. View Article : Google Scholar : PubMed/NCBI
|
32
|
Li S, Zhao Y, He X, Kim TH, Kuharsky DK,
Rabinowich H, Chen J, Du C and Yin XM: Relief of extrinsic pathway
inhibition by the Bid-dependent mitochondrial release of Smac in
Fas-mediated hepatocyte apoptosis. J Biol Chem. 277:26912–26920.
2002. View Article : Google Scholar : PubMed/NCBI
|
33
|
Broaddus VC, Dansen TB, Abayasiriwardana
KS, Wilson SM, Finch AJ, Swigart LB, Hunt AE and Evan GI: Bid
mediates apoptotic synergy between tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) and DNA damage. J Biol Chem.
280:12486–12493. 2005. View Article : Google Scholar : PubMed/NCBI
|
34
|
Orzechowska EJ, Kozlowska E, Czubaty A,
Kozlowski P, Staron K and Trzcinska-Danielewicz J: Controlled
delivery of BID protein fused with TAT peptide sensitizes cancer
cells to apoptosis. BMC Cancer. 14:7712014. View Article : Google Scholar : PubMed/NCBI
|
35
|
Wilkinson JC, Cepero E, Boise LH and
Duckett CS: Upstream regulatory role for XIAP in receptor-mediated
apoptosis. Mol Cell Biol. 24:7003–7014. 2004. View Article : Google Scholar : PubMed/NCBI
|
36
|
Zhang XD, Zhang XY, Gray CP, Nguyen T and
Hersey P: Tumor necrosis factor-related apoptosis-inducing
ligand-induced apoptosis of human melanoma is regulated by
smac/DIABLO release from mitochondria. Cancer Res. 61:7339–7348.
2001.PubMed/NCBI
|
37
|
Rao SS, O'Neil J, Liberator CD, Hardwick
JS, Dai X, Zhang T, Tyminski E, Yuan J, Kohl NE, Richon VM, et al:
Inhibition of NOTCH signaling by gamma secretase inhibitor engages
the RB pathway and elicits cell cycle exit in T-cell acute
lymphoblastic leukemia cells. Cancer Res. 69:3060–3068. 2009.
View Article : Google Scholar : PubMed/NCBI
|